Evosep

Executive Summary

Evosep, a Danish biotechnology company founded in 2016, is pioneering standardized, automated sample preparation and liquid chromatography solutions for mass spectrometry-based proteomics. By targeting a 10-fold increase in speed and a 100-fold improvement in robustness, Evosep aims to transform protein-based clinical diagnostics and enable large-scale precision medicine. The company’s technology addresses key bottlenecks in proteomic workflows, making them more accessible for routine clinical use and large cohort studies. With its headquarters in Odense, Evosep is well-positioned to capitalize on the growing demand for high-throughput proteomics in drug development and diagnostics. The company’s platform has the potential to unlock new insights in biomarker discovery and disease monitoring, offering a standardized alternative to fragmented current methods. As the proteomics market expands, driven by advancements in mass spectrometry and the need for reproducible clinical assays, Evosep’s solutions could become integral to both academic research and clinical labs. While still in its growth phase, the company’s focus on robustness and automation aligns with key industry trends, positioning it for strategic partnerships and further adoption in the coming years.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation Evosep One system with enhanced throughput70% success
• Q2 2027Strategic partnership with a top-10 pharmaceutical company for clinical proteomics50% success
• Q1 2028FDA clearance of first diagnostic assay based on Evosep platform40% success